TNF Pharmaceuticals Stock Price, News & Analysis
Company Description
TNF Pharmaceuticals, Inc. (formerly trading on Nasdaq under the symbol TNFA) has undergone a significant corporate transformation and is now known as Q/C Technologies, Inc., which trades on Nasdaq under the ticker QCLS. According to an 8-K filing, the company filed a Certificate of Amendment to change its name from TNF Pharmaceuticals, Inc. to Q/C Technologies, Inc. effective September 22, 2025, and its common stock ceased trading under the symbol TNFA and began trading under QCLS on the Nasdaq Stock Market before the open of trading on September 25, 2025. This page therefore serves as a historical overview of the business that was associated with the TNFA symbol and its subsequent pivot.
Prior to the name and symbol change, TNF Pharmaceuticals, Inc. was described in multiple press releases as a clinical stage pharmaceutical company focused on extending healthy lifespan. The company concentrated on developing two novel therapeutic platforms aimed at treating the causes of disease rather than only addressing symptoms. Its lead platform, isomyosamine, is based on a clinical stage small molecule that regulates the immune system to control TNF-α and other pro-inflammatory cytokines. Isomyosamine was being developed for diseases and disorders marked by acute or chronic inflammation, including autoimmune and inflammatory conditions. The second platform, Supera-CBD, is a novel synthetic derivative of cannabidiol (CBD) being developed for chronic pain, addiction and epilepsy, with the stated goal of improving upon existing CBD-based products and drugs.
In addition to its therapeutic focus, TNF Pharmaceuticals entered into a new line of business centered on light-based, quantum-inspired computing for cryptocurrency and blockchain applications. In a Business Wire release, the company announced that it had secured exclusive global rights to use LightSolver Ltd.'s laser-based processing unit (LPU) technology in cryptocurrency and blockchain applications. LightSolver's LPU is described as the first laser-based processing unit harnessing light for computation, designed to outpace conventional GPUs, quantum computing and high-performance computing in speed and efficiency, and to reduce energy costs by up to 90% in cryptocurrency applications. TNF stated that this technology is intended to solve compute-intensive combinatorial and physical problems at the speed of light and to provide a potential pathway to more sustainable crypto infrastructure.
Following this licensing agreement and related transactions, the company described its new identity as Q/C Technologies, emphasizing a strategic pivot into quantum-class photonic computing and energy-efficient blockchain infrastructure. In its news releases, Q/C Technologies is characterized as pioneering the next generation of energy-efficient quantum class, high-performance computing infrastructure. Through a licensing agreement with LightSolver, Q/C holds exclusive rights to use quantum-inspired, laser-based processing units to address compute-intensive problems at the speed of light, particularly in cryptocurrency and blockchain verticals. The company positions this as bridging a disruptive computing paradigm for high-speed photonic computing with cryptocurrency infrastructure development at scale, with the aim of unlocking performance and sustainability for next-generation blockchain applications and post-quantum security.
During the transition period, TNF Pharmaceuticals also reported several corporate and capital structure events. An 8-K filing details a Securities Purchase Agreement for a private placement of newly designated Series H convertible preferred stock and accompanying warrants, with gross proceeds expected to be $7 million, and related placement agent arrangements. Another 8-K filing describes the creation of Series I convertible preferred stock in connection with a Membership Interest Purchase Agreement to acquire 100% of the membership interests of LPU Holdings LLC, as well as amendments to existing Series F and Series F-1 preferred stock designations to extend their maturity dates and remove amortization terms. These steps were part of the financing and structural arrangements supporting the company's new computing-focused strategy.
Before the pivot, TNF Pharmaceuticals issued releases describing efforts to strengthen its financial position and maintain its Nasdaq listing. The company announced a reverse stock split at a ratio of 1-for-100 to support compliance with Nasdaq listing requirements and later reported that it had regained compliance with Nasdaq's minimum bid price rule after its shares maintained a minimum bid price of $1.00 for 10 consecutive business days. Another release highlighted a material reduction in liabilities over several months and described this as providing a stronger platform for growth opportunities and shareholder value creation.
TNF Pharmaceuticals also reported on its clinical and collaborative activities. One release describes a philanthropic collaboration with the DADA2 Foundation to initiate a Compassionate Use (Expanded Access) study evaluating isomyosamine as a potential treatment for DADA2, a rare pediatric autoinflammatory disease. The company characterized isomyosamine as an orally administered small molecule TNF-alpha inhibitor with anti-inflammatory action and minimal or no immunosuppression, and suggested it could be a potential alternative to biologic TNF inhibitors in that setting. Additional communications referenced ongoing collaboration with Renova on GLP-induced inflammation and muscle damage, as part of the broader development program for its therapeutic platforms.
From a regulatory reporting perspective, TNF Pharmaceuticals filed a Form 12b-25 (NT 10-Q) indicating that it was unable to file its Quarterly Report on Form 10-Q for the six months ended June 30, 2025, within the prescribed time period without unreasonable effort or expense. The company stated that it required additional time to complete and finalize the financial statements required for that report and anticipated filing within the allowed extension period.
Investors researching the historical TNFA symbol should note that, based on the 8-K filed on September 26, 2025, the TNFA ticker has been replaced by QCLS on Nasdaq and the corporate name has changed to Q/C Technologies, Inc. The name change did not affect the rights of the company's security holders, and the CUSIP number remained the same. For current trading information and ongoing business developments, users should refer to Q/C Technologies under the symbol QCLS, while TNFA-related materials provide historical context for the company's evolution from a clinical stage biopharmaceutical issuer into a business focused on quantum-class photonic computing and blockchain infrastructure.
Business evolution under the TNFA symbol
While trading as TNFA, the company communicated a dual focus over time. Initially, its core identity was as a clinical stage pharmaceutical company with two main drug platforms, isomyosamine and Supera-CBD, targeting inflammatory and neurological conditions and aiming to treat underlying disease mechanisms. Later, the company added a second major pillar by entering into the LightSolver licensing agreement and acquiring LPU Holdings LLC, thereby adding a computing and blockchain infrastructure business line. Subsequent press releases and the name change to Q/C Technologies indicate that this computing-focused strategy became the primary direction, with the company continuing to "evaluate strategic options" for its legacy therapeutic programs with the goal of maximizing value from those assets.
Regulatory and listing context
TNF Pharmaceuticals' filings and news demonstrate active management of its regulatory and listing status. The reverse stock split and subsequent confirmation of compliance with Nasdaq's minimum bid price requirement show steps taken to maintain a Nasdaq Capital Market listing. The NT 10-Q filing reflects the company's use of the SEC's extension mechanism when additional time was needed to finalize quarterly financial statements. Multiple 8-K and 8-K/A filings provide detail on financing transactions, preferred stock designations, acquisition of LPU Holdings LLC, and the license agreement with LightSolver, as well as the formal corporate name and ticker symbol changes.